These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 5763049)

  • 1. Irreversible enzyme inhibitors. CXXXIX. p-(4,6-Diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. VI. Further studies on effects of substitution on the propionamide bridge on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):92-4. PubMed ID: 5763049
    [No Abstract]   [Full Text] [Related]  

  • 2. Irreversible enzyme inhibitors. 108. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. IV. Effects of substitution on the propionamide bridge on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jul; 11(4):672-7. PubMed ID: 5244345
    [No Abstract]   [Full Text] [Related]  

  • 3. Irreversible enzyme inhibitors. CXXIX. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. V. Effects of substitution on the benzenesulfonyl fluoride moiety on isozyme specificity.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jul; 11(4):677-82. PubMed ID: 5244346
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible enzyme inhibitors. CXXVII. p-(2,6-diamino-1,2-dihydro--2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. 3. Effects of modification of the propionamide bridge on isozyme specificity.
    Baker BR; Luorens GJ
    J Med Chem; 1968 Jul; 11(4):666-72. PubMed ID: 5244344
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible enzyme inhibitors. CXLI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[p-(p-fluorosulfonylphenylureidomethyl)phenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):101-4. PubMed ID: 5763002
    [No Abstract]   [Full Text] [Related]  

  • 6. Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):38-41. PubMed ID: 5237173
    [No Abstract]   [Full Text] [Related]  

  • 7. Irreversible enzyme inhibitors. CIX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. 3.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):26-33. PubMed ID: 5237171
    [No Abstract]   [Full Text] [Related]  

  • 8. Irreversible enzyme inhibitors. CXL. Active-site-directed irreversible inhibitors derived from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Lourens GJ
    J Med Chem; 1969 Jan; 12(1):95-101. PubMed ID: 5763050
    [No Abstract]   [Full Text] [Related]  

  • 9. Irreversible enzyme inhibitors. 143. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-aminophenoxypropyl)-2,4-diamino-6-methylpyrimidine with a terminal sulfonyl fluoride.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jan; 12(1):108-11. PubMed ID: 5763004
    [No Abstract]   [Full Text] [Related]  

  • 10. Irreversible enzyme inhibitors. CXXXVI. 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenzamido)phenoxymethyl]pyrimidine, an active-site-directed irreversible inhibitor of dihydrofolic reductase. Effect of structure on isozyme specificity.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):82-5. PubMed ID: 5763046
    [No Abstract]   [Full Text] [Related]  

  • 11. Irreversible enzyme inhibitors. CX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. IV.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):34-7. PubMed ID: 5237172
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible enzyme inhibitors. CXXXVII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenoxymethyl)-2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine bearing a terminal sulfonyl fluoride.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):86-8. PubMed ID: 5763047
    [No Abstract]   [Full Text] [Related]  

  • 13. Irreversible enzyme inhibitors. CXLII. Further studies on active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-Aminophenoxypropyl)-2,4,6-triaminopyrimidine bearing a terminal sulfonyl fluoride.
    Baker BR; Meyer RB
    J Med Chem; 1969 Jan; 12(1):104-7. PubMed ID: 5763003
    [No Abstract]   [Full Text] [Related]  

  • 14. Irreversible enzyme inhibitors. 138. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenethyl)-- 2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine with a terminal sulfonyl fluoride.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):89-91. PubMed ID: 5763048
    [No Abstract]   [Full Text] [Related]  

  • 15. Irreversible enzyme inhibitors. CXXXVI. 2,4-Diamino-5-(3,4-dichlorophenyl)-6-[p-(m-fluorosulfonylbenz amido) phenoxymethyl] pyrimidine, an active-site-directed irreverisible inhibitor of dihydrofolic reductase. Effect of structure on isozyme specificity.
    Baker BR; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):82-5. PubMed ID: 5777842
    [No Abstract]   [Full Text] [Related]  

  • 16. Irreversible enzyme inhibitors. CLIX. Effect of substitution on transport and isozyme specificity of p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)-o-chlorophenoxyacetamido-benzenesulfonyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase.
    Baker BR; Ashton WT
    J Med Chem; 1969 Sep; 12(5):894-7. PubMed ID: 5812207
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible enzyme inhibitors. 178. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 1-(4-benzyloxy-3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1161-5. PubMed ID: 5479857
    [No Abstract]   [Full Text] [Related]  

  • 18. Irreversible enzyme inhibitors. CXIX. Active-site-directed irreversible inhibitors of dihydrofolic reductase with tissue specificity derived from 2,4,6-triaminopyrimidine with a terminal sulfonyl fluoride at the 5 position.
    Baker BR; Meyer RB
    J Med Chem; 1968 May; 11(3):489-94. PubMed ID: 5241408
    [No Abstract]   [Full Text] [Related]  

  • 19. Irreversible enzyme inhibitors. CLXXIX. Active-site-directed irreversible enzyme inhibitors of dihydrofolate reductase from 1-(3-chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine with oxyamide bridges to a terminal sulfonyl fluoride.
    Baker BR; Ashton WT
    J Med Chem; 1970 Nov; 13(6):1165-70. PubMed ID: 5479858
    [No Abstract]   [Full Text] [Related]  

  • 20. Irreversible enzyme inhibitors. CLXXVII. Active-site-directed irreversible inhibitors of dihydrofolate reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(phenylalkylphenyl)-s-triazines. II.
    Baker BR; Vermeulen NM
    J Med Chem; 1970 Nov; 13(6):1154-60. PubMed ID: 5479856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.